BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for Q4 results, cash and share count and increased its operating expense estimates in-line with recent trends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics assumed with an Overweight at Morgan Stanley
- Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks
- Denali Therapeutics Discontinues DNL343 ALS Trial
- Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
- Denali Therapeutics price target lowered to $35 from $38 at B. Riley